[ad_1]
In addition to the Biontech preparation, it is considered one of the European contenders: the vaccine from the pharmaceutical company AstraZeneca and the University of Oxford offers 70 percent protection, according to the company.
By Thomas Spickhofen, ARD-Studio London
Another company, British-Swedish pharmaceutical company AstraZeneca, has presented positive data on vaccine development. The new coronavirus vaccine developed by the University of Oxford has an average effectiveness of 70 percent, the company said.
The result lags behind the values of the Pfizer / Biontech and Moderna preparations. However, if you only administer half a dose initially and a full dose a month later, the vaccine will be 90 percent effective, AstraZeneca says. It should also be significantly cheaper, much easier to store and transport around the world than other vaccines.
The EU has ordered 300 million doses of the vaccine
According to the company, the vaccine works in different ages, including the elderly. There are also signs that it could slow the spread of the corona virus, the developers say. 20,000 volunteers in the UK and Brazil participated in the series of tests.
The AstraZeneca vaccine is one that the EU has high hopes for. She has already ordered 300 million cans. The British government has also ordered 100 million cans. She wants to start getting vaccinated before Christmas and hopes to gradually return to normal after Easter. Overall, AstraZeneca says it is gearing up to initially manufacture three billion cans worldwide.
